LVADs for Advanced Heart Failure: Magnetic Levitation Gains Momentum

Final analysis of MOMENTUM-3 establishes superiority of a magnetically levitated left ventricular assist device.

In the manufacturer-sponsored MOMENTUM-3 trial, investigators enrolled patients with advanced heart failure who were deemed eligible for a left ventricular assist device (LVAD) as destination therapy or as a bridge to transplantation. A total of 1028 patients (median age, 62; 81% men; mean left ventricular ejection fraction, 17%) were randomized to a fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD; HeartMate 3) or a traditional axial-flow device (HeartMate 2). Interim analyses found markedly lower risks for pump thrombosis and lower risks for nondisabling strokes with the magnetically levitated device than with the axial-flow device (NEJM JW Cardiol Apr 2018 and N Engl J Med 2018; 378:1386). Now, the MOMEN…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

LVADs for Advanced Heart Failure: Magnetic Levitation Gains Momentum

Topics

Reviewing Author